Tetra Bio-Pharma Signs Distribution Agreement with Aphria

Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) signed an agreement deal with Aphria (TSX:APH) to start promoting a co-developed medical cannabis blend product.
As quoted in the press release:

Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princeps, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.
Rx Princeps will be a new option for doctors who want to prescribe medical cannabis, while ensuring that their patients will receive a consistent and high-quality product. Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada, thereby complying with the quality standards Tetra wants to bring to the medical community and its patients.

Click here to read the full press release.

Source: www.marketwired.com